ORZORA: Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status
Sandro Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Andrew R. Clamp, Radosław Mądry(Nordic Society of Gynecologic Oncology), Geoff Hall(University of Leeds), Rosalind Glasspool(Institut Bergonié), Imre Pete(National Institute of Oncology), Jaroslav Klát(University Hospital Ostrava), Amit M. Oza(Ontario Institute for Cancer Research), David Cibula(Charles University), Alan Barnicle(AstraZeneca (United Kingdom)), Beatriz Pardo(Duran i Reynals Hospital), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Ana Herrero(Hospital Universitario Miguel Servet), Nicoletta Colombo(University of Milano-Bicocca), Rosie Taylor(AstraZeneca (United Kingdom)), Christopher Blakeley(AstraZeneca (United Kingdom)), Rumyana Ilieva, Constanta Timcheva
Cited by 5
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k